Early sympathetic islet neuropathy in autoimmune diabetes: lessons learned and opportunities for investigation
This review outlines the current state of knowledge regarding a unique neural defect of the pancreatic islet in autoimmune diabetes, one that we have termed early sympathetic islet neuropathy (eSIN). We begin with the findings that a majority of islet sympathetic nerves are lost near the onset of type 1, but not type 2, diabetes and that this nerve loss is restricted to the islet. We discuss later work demonstrating that while the loss of islet sympathetic nerves and the loss of islet beta cells in type 1 diabetes both require infiltration of the islet by lymphocytes, their respective mechanisms of tissue destruction differ. Uniquely, eSIN requires the activation of a specific neurotrophin receptor and we propose two possible pathways for activation of this receptor during the immune attack on the islet. We also outline what is known about the functional consequences of eSIN, focusing on impairment of sympathetically mediated glucagon secretion and its application to the clinical problem of insulin-induced hypoglycaemia. Finally, we offer our view on the important remaining questions regarding this unique neural defect.
KeywordsAutoimmunity Diabetes Glucagon Human Insulin-induced hypoglycaemia Islet Neuropathy Neurotrophins Review Rodent Sympathetic nerves
Brain-derived neurotrophic factor
Diabetic autonomic neuropathy
Early sympathetic islet neuropathy
Lymphocytic choriomeningitis virus
Nerve growth factor
p75 neurotrophin receptor
Rat insulin promoter–glycoprotein
Reactive oxygen species
In 1921, before the discovery of the glucose-lowering agent, insulin, the prospects for individuals with type 1 diabetes were grim: morbidity and early mortality were both very high . Insulin provided a life-saving treatment for this disease . However, while early experience with this new treatment revealed that insulin injection reversed diabetic hyperglycaemia, it also occasionally caused hypoglycaemia, which in severe cases resulted in convulsions, coma or death. The discovery of a glucose-raising agent in pancreatic extracts , subsequently named glucagon, provided a potential treatment for this hypoglycaemia. It was later found that pharmacology mimicked physiology: in non-diabetic individuals insulin-induced hypoglycaemia (IIH) stimulated a marked increase in endogenous glucagon secretion , which in turn limited the severity of the hypoglycaemia and contributed to restoration of euglycaemia [4, 5]. Unfortunately, the ability of individuals with type 1 diabetes to recover from hypoglycaemia after insulin injection is limited by a major impairment in their glucagon response to IIH , one that is present in the first year after diabetes onset . This impaired glucagon response increases the risk of severe and prolonged hypoglycaemia, which is not only dangerous but also aversive . To avoid possible hypoglycaemia, patients sometimes reduce their insulin dose or increase their carbohydrate intake, which decreases their compliance with intensive therapeutic regimes [9, 10]. Such non-compliance may accelerate both the onset and the progression of the long-term complications of this disease [11, 12, 13, 14].
In non-diabetic animals and humans, both branches of the autonomic nervous system and the adrenal medulla are activated by hypoglycaemia . Because each of these can stimulate glucagon secretion , their combined activation makes a major contribution to the glucagon response to IIH . Therefore, an autonomic defect is a strong candidate for being a contributor to the impaired glucagon response to IIH seen in patients with type 1 diabetes [6, 7]. However, early in type 1 diabetes the responses of two of these inputs to the islet, namely parasympathetic neural activation  and adrenal medullary adrenaline (epinephrine) secretion , appear normal. Thus, if an autonomic defect in type 1 diabetes impairs the glucagon response to IIH, this defect is likely to occur in the third autonomic input to the islet, the sympathetic nerves. Therefore we looked for, and found, a major defect in the sympathetic innervation of the islet in autoimmune diabetes, one that we have termed early sympathetic islet neuropathy (eSIN).
Characteristics of nerve loss
Marked loss of islet sympathetic nerves: identification and quantification
The phenotypic characteristics, mechanistic requirements and functional consequences of eSIN
Model of autoimmune diabetes
Human type 1
Islet sympathetic nerves have been specifically identified by immunohistochemistry using different antibodies in different species. For example, in the rat, an antibody against the vesicular monoamine transporter 2 was used  to target the membrane of small noradrenergic secretory vesicles . In the mouse, a neurally specific antibody against neuropeptide tyrosine was employed  to target this peptidergic neurotransmitter located in large non-adrenergic secretory vesicles of sympathetic nerves . In humans , an antibody against tyrosine hydroxylase was used to target this enzyme in the cytoplasm throughout the sympathetic neuron. The sympathetic marker used was selected for each species to minimise non-neural staining, which could obscure the fine nerve fibres and varicosities in the islet and thereby lead to underestimation of nerve area and nerve loss. For example, while vesicular monoamine transporter 2 is neurally specific in rat islets, it is expressed in beta cells of primates, including humans . Similarly, some neuropeptide tyrosine antibodies also bind peptide tyrosine tyrosine, which is found in alpha, beta, delta and F cells of mouse islets . The finding that islet nerve areas, detected by three different antibodies and directed to three different sympathetic compartments, all decreased by a similar degree in animal models and humans with type 1 diabetes suggests that a marked loss of islet sympathetic nerves is a fundamental characteristic of autoimmune diabetes.
Just as antibody selection is important for specifically identifying islet sympathetic nerves, the method chosen for quantifying islet sympathetic nerves is important for accurately determining the magnitude of islet nerve loss in autoimmune diabetes. Experimental experience led us to quantify islet sympathetic nerves as ‘nerve area per islet’ rather than ‘nerve density’ (nerve area/islet area) because in some cases islet area can decrease secondary to beta cell loss without a change in the sympathetic innervation of the islet. In such situations, quantifying islet sympathetic nerve density would lead to the incorrect conclusion that the sympathetic innervation of the islet had actually increased. In contrast, quantifying islet sympathetic nerves by nerve area per islet would lead to the correct conclusion that the sympathetic innervation of the islet had not changed.
The best example of this phenomenon comes from experiments using beta cell toxins, either alloxan (ALX) or streptozotocin (STZ), which destroy beta cells by a mechanism that does not involve lymphocytic infiltration and therefore does not result in the loss of islet sympathetic nerves [19, 20]. High doses of either toxin produce a marked (75%) and rapid (< 1 week) decrease in islet area [19, 20]. If nerve density had been used to quantify islet sympathetic nerves one would have concluded that the sympathetic innervation of the islet had increased threefold. This conclusion would be suspect because, although unmyelinated sympathetic nerves can sprout, arborise and grow, this process takes months, not days . Alternatively, if one used nerve area per islet to quantify islet sympathetic nerves, one would conclude that the sympathetic innervation of the islet was unchanged [19, 20].
To test which of these two methods gave the best functional estimate of the sympathetic innervation of the islet, we activated the postganglionic nerves innervating the islet in both STZ-diabetic rats  and ALX-diabetic mice  and measured the resultant glucagon response. We found that the glucagon response was unchanged, not tripled, when compared with that of non-diabetic controls. We concluded that when autoimmune diabetes results in a decrease in islet area, the sympathetic innervation of the islet is best quantified as nerve area per islet to avoid underestimating the degree of islet sympathetic nerve loss.
Islet selectivity of nerve loss
If the loss of sympathetic nerves in autoimmune diabetes is due to a tissue-specific immune attack, it should occur only in the pancreatic islets and not in the surrounding exocrine pancreas. Indeed, there is no loss of exocrine sympathetic nerves in diabetic BB rats , diabetic NOD mice  or humans with type 1 diabetes , all of whom display a marked loss of their islet sympathetic nerves. Thus, islet-selective nerve loss is a defining characteristic of eSIN in autoimmune diabetes.
Given the presence of intact sympathetic axons in the adjacent exocrine pancreas, one might expect rapid reinnervation of the islets. For example, one of the major barriers preventing regrowth of nerves into denervated tissue, especially in humans, is the long distances involved . However, the intact axons in the exocrine tissue surrounding the islet, which are the parent axons of islet nerves, have a remarkably short distance to grow in order to reinnervate the islet. Furthermore, these fine axons in the exocrine pancreas are unmyelinated, a requirement for nerve regrowth . Finally, islets transplanted into non-diabetic animals are eventually reinnervated . However, in human type 1 diabetes there is no significant reinnervation of the islet, even decades after the initial destruction of islet sympathetic nerves , a finding confirmed over months in the BB diabetic rat . Apparently, some factor of the diabetic milieu inhibits the regrowth of islet sympathetic nerves, despite the short reinnervation distance. Diabetes is known to retard the regrowth of other nerves after crush injury or axotomy, as reviewed by Kennedy and Zochodne . Several potential mechanisms have been proposed to mediate this effect [33, 34, 35, 36, 37, 38, 39, 40, 41, 42]. An alternative hypothesis, specific to the islet, is that a loss of islet nerve growth factor (NGF) inhibits islet reinnervation. Three findings support this hypothesis. First, NGF is a potent growth factor for islet sympathetic nerves . Second, NGF is produced by the islet beta cells [44, 45], which are destroyed in type 1 diabetes. Third, beta cells transplanted into non-diabetic animals are preferentially reinnervated compared with non-beta cells . Thus, loss of beta cell-derived NGF may account for the failure of diabetic islets to reinnervate, thereby explaining the permanence of eSIN in autoimmune diabetes [19, 23].
Autoimmune requirement for nerve loss
In contrast, a role for lymphocytic infiltration in the loss of islet sympathetic nerves has yet to be demonstrated in humans with type 1 diabetes. A major problem in doing so is the paucity of lymphocytes found in the islets of individuals with type 1 diabetes [47, 48]. By the time a person presents with type 1 diabetes, the vast majority of lymphocytes that caused the destruction of their beta cells have apparently left the islet . Indeed, immune cells in the islet are usually found only in individuals with very short diabetes duration  and then only in very small amounts . Together these findings suggest that in humans with type 1 diabetes insulitis is transient, consistent with the view that it is a relapsing–remitting disease [51, 52]. Thus, to relate previous episodes of insulitis to the loss of islet sympathetic nerves in human type 1 diabetes, one needs an index of cumulative insulitis. Because the loss of islet beta cells is thought to be due to insulitis, the degree of an islet’s beta cell loss is likely an index, albeit an indirect one, of that islet’s history of insulitis . Thus, it may be possible to use the degree of beta cell loss to relate ‘cumulative insulitis’ to the loss of islet sympathetic nerves in human type 1 diabetes. Despite the fact that a relation between insulitis and loss of islet sympathetic nerves has yet to be demonstrated in human type 1 diabetes, there is an autoimmune requirement for the loss of islet sympathetic nerves because there is no loss of islet sympathetic nerves in individuals with type 2 diabetes , which is traditionally viewed as a non-autoimmune disease.
Early onset of nerve loss
While infiltration of the islet is required for the loss of its sympathetic nerves in animal models of autoimmune diabetes, it was not initially clear if the nerve loss was rapid, like that mediated by active pruning , or slow, like that due to the chronic neural degeneration seen in classical diabetic autonomic neuropathy (DAN) [55, 56]. Fortunately, the differing time courses and magnitudes of infiltration found in the various animal models of autoimmune diabetes have answered this question. In the BB rat , NOD mouse  and RIP-GP mouse  islet nerve loss is observed within 1–2 weeks of diabetes onset, suggesting an active and rapid pruning of islet sympathetic nerves. Importantly, in human type 1 diabetes, loss of islet sympathetic nerves has also been demonstrated 1–2 weeks after diabetes onset . Thus, in rats, mice and humans, the islet nerve loss occurs very early in the course of autoimmune diabetes.
The slow and progressive infiltration that precedes diabetic hyperglycaemia in the NOD mouse presents an opportunity to better define the onset of nerve loss. Before diabetes onset, a minority of islets already have evidence of heavy lymphocytic infiltration and those islets also display a marked loss of islet sympathetic nerves . Subsequently, the predictable timing of islet infiltration offered by the inducible diabetes of the RIP-GP mouse has proved to be instrumental in identifying exactly when islet sympathetic nerves are lost. Four days after LCMV injection neither infiltration nor nerve loss is observed in the islets of these mice . However, 7 days after LCMV injection there is a marked infiltration of the islet accompanied by marked loss of islet sympathetic nerves  despite the fact that diabetic hyperglycaemia does not appear until 2 days later. Thus, we conclude from these studies that islet sympathetic nerves are destroyed coincident with islet infiltration and that by the time enough beta cells are destroyed to produce hyperglycaemia a majority of islet sympathetic nerves have already been lost.
Mechanism of nerve loss
The role of the p75 neurotrophin receptor
Several mechanisms with the potential to cause eSIN have been ruled out. For example, the slow deterioration of nerve function that characterises DAN and somatosensory neuropathy (SSN) differs in two ways from that causing the rapid onset of eSIN. First, DAN and SSN occur in both type 1 and type 2 diabetes, but eSIN occurs only in type 1 diabetes . Second, the development of both DAN and SSN is linked to chronic hyperglycaemia, yet eSIN occurs even before diabetic hyperglycaemia develops [20, 22]. Also, in eSIN the loss of islet sympathetic nerves is not caused by the loss of islet beta cells because eSIN does not occur in either ALX-diabetic mice  or STZ-diabetic rats  who have lost enough beta cells to require insulin treatment. Finally, although the lymphocytic infiltration of the islet somehow triggers eSIN, it is unlikely that invading T lymphocytes directly attack sympathetic nerves because the parent axons of these islet nerves, which reside in the adjacent exocrine pancreas, remain intact [19, 20, 23].
The discussion above suggests that the destructive effect of invading lymphocytes on islet sympathetic nerves is indirect, perhaps by activation of pruning receptors on sympathetic axons. Activation of one such receptor, the p75 neurotrophin receptor (p75NTR), results in the rapid pruning of sympathetic axons in various tissues during late development . To determine whether the p75NTR plays a similar role in the rapid loss of islet sympathetic nerves seen early in autoimmune diabetes, we knocked out p75ntr (also known as Ngfr) in RIP-GP mice . These mice become diabetic after LCMV injection, as do p75ntr wild-type mice, but unlike wild-type mice, p75ntr-knockout mice retain their islet sympathetic nerves both immediately before diabetes onset and 3 weeks thereafter . Thus, the lymphocytic attack of the islet causes the loss of both islet sympathetic nerves and islet beta cells, but by different mechanisms. Although these studies established that the p75NTR is required for the loss of islet sympathetic nerves, they did not determine the mechanism by which this receptor is activated in autoimmune diabetes.
Activation of the p75NTR
It is known from in vitro studies that low levels of NGF are permissive for BDNF to prune sympathetic axons  (Fig. 4). Thus, this transient protection could be caused by an increase in NGF production and its subsequent stimulation of the axonal maintenance receptor tropomyosin receptor kinase A, which also resides on sympathetic axons (Fig. 4). We therefore looked for, and found, increased basal NGF expression in Bdnf heterozygous islets (Fig. 3). This finding strengthens the possibility that increased NGF helps to protect islet sympathetic nerves from early destruction. Because several lines of evidence suggest that beta cells are the major [44, 45, 46, 59], but not the only , source of islet NGF, near complete destruction of these cells by 3 weeks of diabetes may also explain why this early protection of islet sympathetic nerves is not maintained over time. However, studies are needed to quantify the decrease in islet NGF protein that actually results from the autoimmune destruction of islet beta cells and to determine whether the increase in islet NGF seen in Bdnf heterozygotes (Fig. 3) is actually sufficient to protect islet sympathetic nerves. There is also a need for measurements of BDNF in islets before, during and after the onset of autoimmune diabetes to define the respective roles of NGF and BDNF in both the healthy retention and the pathological loss of islet sympathetic nerves. The recent development of a non-viral method to induce autoimmune diabetes in RIP-GP mice , which we show here is also characterised by eSIN (Fig. 1), now increases the feasibility of making such measurements.
With regard to a ligand-independent factor that might activate the p75NTR, we searched for one that would be increased during the autoimmune attack on the islet. In vitro studies have shown that reactive oxygen species (ROS) activate γ-secretase within the cell membrane, which in turn frees the intracellular domain of the p75NTR for downstream signalling . More recent studies demonstrate that this ligand-independent activation of p75NTR also results in axonal degeneration, at least in vitro . Such a mechanism of p75NTR activation is plausible in autoimmune diabetes because ROS is known to be generated in islets under autoimmune attack  (see also Fig. 4). Further, the reagents needed to test this proposed mechanism are available since inhibitors of γ-secretase have been developed as a potential treatment for Alzheimer’s disease . However, more selective Notch-sparing γ-secretase inhibitors  are required for use in animal models of autoimmune diabetes: Notch, another substrate for γ-secretase, is involved in the development and maturation of the lymphocytes  that cause autoimmune diabetes . If islet ROS activates the p75NTR by this ligand-independent mechanism, then Notch-sparing inhibition of γ-secretase should prevent the loss of islet sympathetic nerves during the immune attack on the islet.
In summary, although p75NTR is required for the loss of islet sympathetic nerves during the immune attack on the islet, the molecules and pathways responsible for activating this receptor in autoimmune diabetes have yet to be convincingly demonstrated. However, it is worth noting that the link between immune cell infiltration and loss of sympathetic nerves is not restricted to autoimmune diabetes. For example, there is a loss of sympathetic nerves in the inflamed intestine of patients with Crohn’s disease  and in the inflamed joints of patients with rheumatoid arthritis . The common factor in the loss of sympathetic nerves among these three diseases is the infiltrate, not the tissues infiltrated. Thus, to activate the p75NTR, the invading lymphocytes either secrete BDNF or induce the production of BDNF or ROS in a tissue-independent fashion.
Functional consequences of nerve loss
Impaired glucagon response to sympathetic activation
In both diabetic BB rats and diabetic NOD mice, the major loss of islet sympathetic nerves results in a marked impairment of the glucagon response to either electrical  or chemical  activation of postganglionic sympathetic nerves. The findings in these models directly demonstrate the functional consequence of this nerve loss. However, because the islet nerve loss in human type 1 diabetes has only recently been demonstrated , the effect of this nerve loss on sympathetically mediated glucagon secretion in humans has yet to be determined.
The impaired glucagon response to sympathetic neural activation is not due to dysfunctional alpha cells because adrenaline elicits a normal glucagon response in BB diabetic rats  and an exaggerated glucagon response in humans with type 1 diabetes . The hyper-response in humans may be due to an upregulation of adrenergic receptors on the alpha cell, secondary to loss of islet sympathetic nerves, but experiments specifically designed to directly test this hypothesis are needed. This glucagon impairment is due neither to loss of beta cells nor to diabetic hyperglycaemia because when both are induced by non-immune, chemical destruction of islet beta cells, which does not cause loss of islet sympathetic nerves, the glucagon response to activation of postganglionic sympathetic axons and terminals is not impaired [20, 30]. In contrast, the glucagon impairment seen in autoimmune diabetes, which does cause the loss of islet sympathetic nerves, is likely due to decreased neurotransmitter release. In support of this interpretation, pre-treating non-diabetic rodents with 6-hydroxydopamine, which reproduces the degree of islet sympathetic nerve loss seen in diabetic BB rats, NOD mice and RIP-GP mice, markedly decreases the release of the sympathetic neurotransmitter noradrenaline (norepinephrine) and reproduces the impairment of the glucagon response to postganglionic sympathetic neural activation seen in these models of autoimmune diabetes [20, 22, 70].
Impaired glucagon response to insulin-induced hypoglycaemia
Individuals with type 1 diabetes have an impaired glucagon response to IIH within the first year after diagnosis . Pancreatic sympathetic nerves in non-diabetic animals are activated during marked and severe hypoglycaemia (glucose ≈1.9 mmol/l and ≈0.8 mmol/l, respectively) [72, 73]. Hence, the loss of islet sympathetic nerves in humans with type 1 diabetes is a potential contributor to the impaired glucagon responses seen at these levels of hypoglycaemia. Consistent with this interpretation, individuals with type 2 diabetes, who do not lose islet sympathetic nerves , have a normal glucagon response to IIH, at least for the first decade after diabetes diagnosis .
In contrast, because the pancreatic sympathetic nerves of non-diabetic animals are not activated by mild hypoglycaemia (glucose ≈3.9 mmol/l), eSIN cannot account for the impairment of the glucagon response seen in diabetic animals at this level of hypoglycaemia . However, factors intrinsic to the alpha cell have been shown to stimulate glucagon secretion when glucose levels fall, and these factors may be impaired in diabetes . Similarly, diabetes-induced changes in islet paracrine factors, such as somatostatin and insulin, may also account for the alpha cell’s impaired response to mild hypoglycaemia. For example, blocking the action of somatostatin from neighbouring islet delta cells improves the glucagon response to hypoglycaemia in diabetic animals . Also, insulin or other beta cell secretory products (68–70) are thought to tonically restrain glucagon secretion. Because even mild hypoglycaemia is sufficient to totally inhibit insulin secretion in non-diabetic individuals , mild hypoglycaemia may eliminate the tonic inhibitory effects of the beta cell on adjacent alpha cells . Loss of this beta cell switch-off in diabetic animals could therefore impair the glucagon response to mild hypoglycaemia [75, 80]. However, it is unlikely to account for the major impairment of the larger glucagon responses seen at marked or severe hypoglycaemia for the following reasons. In non-diabetic humans and animals there is no further decrease of insulin at these levels of hypoglycaemia, implying that the larger glucagon responses seen are due to recruitment of other stimulatory factors as hypoglycaemia deepens . Therefore, diabetes-induced defects in these other factors, including islet sympathetic nerves, are likely responsible for the glucagon impairment at these levels of hypoglycaemia.
Relative contribution of eSIN
While the data above would suggest that the relative contributions made by eSIN and intrinsic and paracrine factors to the impaired glucagon response to IIH depend on the severity of hypoglycaemia, a definitive study of their relative contribution has yet to be performed. Currently, there are barriers to correctly performing and correctly interpreting such studies In particular, the inhibitory effect of short-term diabetic hyperglycaemia on sympathetic ganglia and the inhibitory effect of exogenous insulin on alpha cell responsiveness must be accounted for. A recent study has shown that even 1 week of severe hyperglycaemia can impair neurotransmission across coeliac ganglia . Since coeliac ganglia project sympathetic nerves to the pancreas , such impaired ganglionic neurotransmission results in the impairment of sympathetically mediated glucagon responses when preganglionic nerves are activated . This implies that previous conclusions that the impaired glucagon response to IIH in diabetic animals is due solely to loss of beta cell switch-off may need to be amended to include the contribution of a previously unrecognised impairment in the sympathetic islet pathway.
In addition, exogenous insulin is known to decrease the responsiveness of the alpha cell to stimuli [82, 83] and this inhibitory effect of exogenous insulin may be increased in type 1 diabetes . Thus, even when the degree of hypoglycaemia is experimentally matched between non-diabetic individuals and those with type 1 diabetes, one needs to experimentally match the inhibitory effect of exogenous insulin per se on glucagon secretion in the two groups. Therefore, to determine the contribution made by eSIN to the impairment of the glucagon response to IIH, the experimental design must account for the following: (1) the severity of the hypoglycaemia; (2) the inhibitory effect of prior hyperglycaemia on sympathetic ganglionic neurotransmission and (3) the inhibitory effect of exogenous insulin on the responsiveness of the alpha cell.
Summary and future directions
A comprehensive summary of studies of the characteristics, mechanism and functional consequences of eSIN is provided in Table 1. In brief, there is an early, marked and islet-selective loss of sympathetic nerves both in animal models of autoimmune diabetes and in humans with type 1 diabetes. This nerve loss is sufficient to impair sympathetically mediated glucagon secretion in animals and may contribute to the impaired glucagon response to IIH seen in humans with type 1 diabetes. Lymphocytic infiltration of the islet and subsequent activation of the p75NTR are required for the nerve loss, at least in animal models of autoimmune diabetes.
Future studies to define the agonist or activator of the p75NTR are needed to complete our understanding of the mechanism by which eSIN occurs. Further studies are also needed to determine the contribution of eSIN to the impaired glucagon response to IIH, in both human type 1 diabetes and in animal models thereof. Such studies would solidify the clinical relevance of eSIN. However, such experiments must be carefully designed to account for ganglionic impairment, a second dysfunction within the islet sympathetic pathway. Finally, since eSIN occurs before the onset of overt diabetes, future studies should focus on reversing, rather than preventing, this unique neuropathy.
We thank M. Bothwell, University of Washington, for helpful discussions regarding ROS and p75NTR activation, and our colleagues at the VA Puget Sound Health Care System and the University of Washington for providing helpful advice on this manuscript. We thank P. Banik, University of Washington, for performing the RT-PCR analysis of islet extracts. In addition, we thank D. Hackney, VA Puget Sound Health Care System, for performing the complex, non-viral induction of diabetes in RIP-GP mice and Q. Mei, University of Washington, for immunohistochemical determination of islet nerve area in these mice. Finally, we kindly thank P. Henderson, VA Puget Sound Health Care System, for administrative assistance.
The studies to determine basal islet expression of BDNF and NGF were performed in part at the Cell Function Analysis Core of the University of Washington’s Diabetes Research Center, which is supported by NIH grant no. P30-DK-017047. This work was supported by a Merit Review from the Biomedical Laboratory R&D Service of the US Department of Veterans Affairs and by US National Institute of Health grant no. R01-DK-050154.
Both authors contributed significantly to the intellectual content of this article, wrote the manuscript and approved this version for publication.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
- 1.Bliss M (2007) The discovery of insulin. University of Chicago Press, ChicagoGoogle Scholar
- 2.Kimball CP, Murlin JR (1923) Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J Biol Chem 58:337–348Google Scholar
- 28.Upchurch BH, Aponte GW, Leiter AB (1994) Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development 120:245–252Google Scholar
- 46.Myersen U, Keymeulen B, Pipeleers DG, Sundler F (1996) Beta cells are important for islet innervation: evidence from purified rat islet-cells grafts. Diabetologia 39:54–59Google Scholar
- 60.Benner C, van der Meulen T, Caceres E, Tigyi K, Donaldson C, Huising M (2014) The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15:620–636CrossRefPubMedPubMedCentralGoogle Scholar